CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse.

ABSTRACT: Relapse following anti-CD19 chimeric antigen receptor (CAR) T cell therapy remains a concern in the treatment of refractory B-cell malignancies. Although the CD19Δexon2 splice variant has been linked to treatment failure, reliable pre-treatment biomarkers for relapse risk are lacking. Here, we analyzed RNA-sequencing data from a small publicly available cohort of four anti-CD19 CAR-T-treated B-cell acute lymphoblastic leukemia patients, including one responder, one non-responder, and two who relapsed after initial response. We quantified the percent spliced in (PSI) of CD19 exon 2, as a proxy for CD19Δexon2 abundance before and after treatment. The patient with the lowest pre-treatment exon 2 PSI (i.e., highest estimated abundance of CD19Δexon2) experienced the earlies

SUBMITTER: Dam SH 

PROVIDER: S-EPMC12935319 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature